查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球女性避孕市场 - 2022-2029
市场调查报告书
商品编码
1143409

全球女性避孕市场 - 2022-2029

Global Female Sterilization Procedures Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

英国的国民健康服务体系 (NHS) 指出，“女性绝育手术是为了永久防止怀孕而进行的手术”。输卵管被阻塞或固定，以防止卵子到达精子并使其受精。

市场动态

对女性健康问题的认识不断提高、人口增长以及研发力度的加大，正在加速全球女性绝育市场的增长。

女性避孕药的研发和人口增长正在推动市场的增长。

女性避孕药具的研发不断增加正在推动全球市场的增长。例如，微针避孕皮肤贴片的开发，一种缓慢释放激素的装置，是一种简单、长效的避孕方法，不需要医疗专业人员进行管理。贴在皮肤上1分钟后，微针迅速从皮肤上的贴片上剥落，缓慢释放左炔诺孕酮约1个月。同样在抗体作为非激素避孕药的研究中，北卡罗来纳大学教堂山分校的研究人员开发了一种与精子结合的强效单克隆抗体，为女性提供了一种廉价的非激素避孕方法。我们的目标是提供另一种预防怀孕的非激素选择。此外，不断增长的世界人口增加了对永久避孕的需求。例如，根据美国人口普查，每 8 秒就有一个人出生，每 12 秒就有一个人死亡。土地、卫生服务和许多其他需求。

缺乏安全性和高成本正在减缓全球女性避孕药具市场的增长。

但是，副作用、缺乏安全性以及女性绝育的高成本等几个原因可能会减缓该市场在预测期内的增长。

COVID-19 影响分析

COVID-19 正在对全球市场增长产生负面影响，因为已经实施了限制措施来限制 COVID-19 的传播，从而扰乱了全球供需链。此外，由于社会化法规的实施，预定的绝育程序被推迟或取消，对全球女性避孕药具市场产生负面影响。

细分分析

预计在预测期间（2022-2029 年），外科手术将以最快的复合年增长率增长。

手术程序具有预测性，因为它们提供的优势，例如是一种高效和永久的避孕方法，不影响性慾，不干扰性自发性。预计在此期间（2022 年）将主导全球市场-2029)。它也不会影响正常的荷尔蒙节律或生理机能。再者，微创手术安全，副作用少，风险小，疗效高（99%），这将确保女性手术绝育在预测期内在全球市场的主导地位。我来了。

区域分析

北美地区主导着全球女性避孕药具市场。

增加意外怀孕、主要市场参与者的存在以及北美更好的成本报销政策有助于该地区在全球市场上的主导地位。例如，美国的意外怀孕率明显高于许多其他发达国家。低收入女性、18-24 岁女性、同居女性和有色人种女性的意外怀孕率最高。在高收入女性、白人女性、受过大学教育的女性和已婚女性中，这一比例似乎最低。此外，根据疾控中心的数据，2020 年将有超过 3,613,647 人出生，出生率为 11.0/1000 人，出生率为 56.0/1000 名 15-44 岁女性，其中未婚母亲将占到这一比例。超过 40.5%。

此外，我们使用 Medicaid 数据确定了 5,906 名接受宫腔镜手术的女性和 23,965 名接受腹腔镜手术的女性，平均年龄为 33 岁。此外，Hologic, Inc.、CONMED Corporation、Ethicon, Inc.、Cooper Surgical、Boston Scientific Corporation、Cardinal Health 和 American Medical Systems 等大公司在全球市场占有很大份额。这些总部设在美国，确保了北美的主导地位。

竞争格局

主要参与者是： Bayer AG、Hologic, Inc.、CONMED Corporation、Ethicon, Inc.、Cooper Surgical、波士顿科学公司、Olympus Corporation、Pregna International、Cardinal Health 和 American Medical Systems。这些主要参与者通过创新、产品发布、合作、收购、合作等方式占领了主要市场份额。例如，2021 年 11 月 30 日，Hologic 收购了 Bolder Surgical。同样在 2022 年 8 月 18 日，拜耳的 Mirena 在美国获得了延长避孕药具使用的批准。

Hologic Inc.

概述。

Hologic 是领先的医疗技术公司之一，致力于研究和製造女性健康产品，包括用于诊断、手术和医学成像的医疗设备。 Hologic 于 1985 年在美国马萨诸塞州成立，是一家全球性公司，在超过 15 个国家设有办事处，拥有 5,500 多名员工。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 提高认识
      • 人口增长
    • 约束因素
      • 缺乏安全性
      • 高成本
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按手术类型

  • 手术
  • 非手术手术
  • 其他

第 8 章最终用户

  • 妇产中心
  • 门诊中心
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 11 章公司简介

  • Hologic, Inc.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Bayer AG
  • CONMED Corporation
  • Ethicon, Inc.
  • Cooper Surgical
  • Boston Scientific Corporation
  • Olympus Corporation
  • Pregna International
  • Cardinal Health
  • American Medical Systems（*LIST NOT EXHAUSTIVE）

第12章 DataM

简介目录
Product Code: DMPH88

Market Overview

National Health Service (NHS) of the U.K states that female sterilization is an operation to prevent pregnancy permanently. The fallopian tubes are either clogged or latched to prevent the eggs from reaching the sperm and fertilizing.

Market Dynamics

The rising awareness about female health issues, the growing population, and the increasing research and development are accelerating the female sterilization procedures market growth globally.

The increasing research and development in female contraception procedures and the growing population propel the market growth.

The increasing research and development in female contraception procedures drive global market growth. For instance, the microneedle contraceptive skin patch development is a device that slow-releases hormones; that is a simple, long-acting form of contraception that does not need a health professional to be administered. Followed by pressing the patch to the skin for one minute, the microneedles will rapidly detach from the patch within the skin and slowly release levonorgestrel for about 1 month. Also, the research on antibodies as a non-hormonal contraceptive, the Scientists at the University of North Carolina at Chapel Hill are developing potent monoclonal antibodies that bind sperm to offer an inexpensive and non-hormonal form of female contraception, offering women another non-hormonal option to prevent pregnancies. Furthermore, the increasing population globally is increasing the need for permanent contraception. For instance, according to the US census, there is one birth every 8 seconds with one death every 12 seconds, and the current global population is ~8 billion, and at this rate will reach 9.8 billion by 2030, which will create a scarcity of food, land, medical services, and many other needs.

The lack of safety and the high cost slow the global female sterilization procedures market growth.

However, some reasons, like the side effects, lack safety, and the high cost of female sterilization procedures, are likely to slow down the growth of this market in the forecast period.

COVID-19 Impact Analysis

COVID-19 disturbed the global supply and demand chain, which has negatively impacted the global market growth as there were restrictions imposed to restrict the spread of COVID-19 infection. Furthermore, because of the socializing restrictions imposed, the planned sterilization procedures were either postponed or canceled, thereby negatively impacting the global female sterilization procedure market.

Segment Analysis

The surgical procedure is anticipated to grow at the fastest CAGR during the forecast period (2022-2029).

The surgical procedure is expected to dominate the global market throughout the forecast period (2022-2029), owing to the advantages offered by the surgical method, such as being a very effective and permanent method of contraception, does not affect sex drive, doesn't interfere with the spontaneity of sexual intercourse. There is no effect on your normal hormonal rhythms or periods. Furthermore, minimally invasive surgery makes it safe, with minimal side effects, risks, and high effectiveness (99%) method, ensuring the dominance of female surgical sterilization over the global market during the forecast period.

Geographical Analysis

The North American region commands the global female sterilization procedures market.

The factors include the growing number of unintended pregnancies, the presence of key market players, and better cost reimbursement policies in North America contribute to the dominance of this region over the global market. For instance, the unintended pregnancy rate is significantly higher in the United States than in many other developed countries. Unplanned pregnancy rates are highest among low-income women, women aged 18-24, cohabiting women, and women of color. Rates appear to be lowest among higher-income women, white women, college graduates, and married women. Furthermore, according to CDC, in 2020, over 3,613,647 births occurred, making the birth rate 11.0 per 1,000 population and the fertility rate 56.0 births per 1,000 women aged 15-44; out of these births, over 40.5% of mothers were unmarried.

Moreover, using the Medicaid data, researchers identified 5,906 women who had undergone hysteroscopic and 23,965 who had undergone laparoscopic sterilization, having an average age of 33. In addition, key market players such as Hologic, Inc., CONMED Corporation, Ethicon, Inc., Cooper Surgical, Boston Scientific Corporation, Cardinal Health, and American Medical Systems hold a large share of the global market. They are U.S.-based, ensuring North America`s dominance globally.

Competitive Landscape

Some key players are: Bayer AG, Hologic, Inc., CONMED Corporation, Ethicon, Inc., Cooper Surgical, Boston Scientific Corporation, Olympus Corporation, Pregna International, Cardinal Health, and American Medical Systems. These key players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and alliances. For instance, in November 30, 2021, Hologic acquired Bolder Surgical. Also, in August 18, 2022, Mirena from Bayer secured approval in the US for an extended duration of use in contraception.

Hologic, Inc.

Overview:

Hologic, Inc. is among the leading medical technology companies involved in research and manufacturing products for women's health, including medical devices for diagnostics, surgery, and medical imaging. Hologic, Inc. is headquartered in Massachusetts, U.S. and was founded in 1985; it also has a global presence, With locations in over 15 countries and more than 5,500 employees globally.

Product Portfolio:

The product portfolio of Hologic, Inc. for female sterilization procedures has JustRight Surgical Stapler, Omni hysteroscope, CoolSeal Vessel Sealing Portfolio, Etc.

The global female sterilization procedures market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Awareness
      • 4.1.1.2. Growing Population
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Safety
      • 4.1.2.2. High Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Procedure Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type Segment
    • 7.1.2. Market Attractiveness Index, By Procedure Type Segment
  • 7.2. Surgical
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-Surgical
  • 7.4. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Maternity Centers
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Ambulatory Centers
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Company Profiles

  • 11.1. Hologic, Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Bayer AG
  • 11.3. CONMED Corporation
  • 11.4. Ethicon, Inc.
  • 11.5. Cooper Surgical
  • 11.6. Boston Scientific Corporation
  • 11.7. Olympus Corporation
  • 11.8. Pregna International
  • 11.9. Cardinal Health
  • 11.10. American Medical Systems(*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us